AI-powered bioinformatics company PathAI has entered into a strategic partnership with AI-powered data solutions provider ConcertAI to develop an AI-powered histopathology solution. The terms and financial details of the partnership have not been disclosed.
The partnership will combine PathAI’s tumor microenvironment panel PathExplore with ConcertAI's Patient360 and RWD360 products to create a new quantitative histopathology and clinical real-world data solution.
The combined solution will be offered to biotech and pharmaceutical companies with the initial focus on a number of cancers including bladder cancer and prostate cancer.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.